Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy

Bone Marrow Transplantation

Volumn 42, Issue 8, 2008, Pages 507-513

  Dallorso, S ^a   Berger, M ^b   Caviglia, I ^a   Emanueli, T ^a   Faraci, M ^a   Scarso, L ^a   Fagioli, F ^b   Haupt, R ^a  

^a G GASLINI INSTITUTE   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

APHERESIS; ARTICLE; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; BONE PAIN; CD34 SELECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HEMATOPOIESIS; HUMANS; INFANT; MALE; MYELOID CELLS; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; TIME FACTORS;

EID: 55549132250     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.206     Document Type: Article

References (25)

1. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 45 1296-1304.
2. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000; 36 (Suppl 1): S11-S14.
3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
4. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
5. Molineux G. Pegfilgrastim: Using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14: 259-264.
6. Curran MP, Goa KL. Pegfilgrastim. Drugs 2002; 62: 1207-1213. Discussion 1214-1215.
7. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
8. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003; 10: 715-724.
9. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by fow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
10. Viscoli C, Castagnola E. Prophylaxis and empirical therapy for infection in cancer patients. In: Mandell GL, Bennett JE, Doolin R (eds). Principles and Practice of Infectious Diseases. Churchill Livingstone: Philadelphia, 2005, pp 3442-3462.
11. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
12. te Poele EM, Kamps WA, Tamminga RY, Leeuw JA, Postma A, de Bont ES. Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol 2005; 27: 627-629.
13. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle peg.lgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005; 27: 449-451.
14. Andre N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 2007; 18: 277-281.
15. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
16. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231.
17. Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417-1423.
18. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U et al Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006; 133: 533-537.
19. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180-185.
20. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J et al Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation 2007; 39: 743-750.
21. Dallorso S, Dini G, Miano M, Rivabella L, Scarso L, Martinengo M et al. G-CSF primed peripheral blood progenitor cells (PBPC) autotransplantation in stage IV neuroblastoma and poor risk solid tumors. Bone Marrow Transplant 1996; 18 (Suppl 2): 182-184.
22. Dolgopolov I, Andreeva L, Yankelevich M, Mscheidze D, Siegel S, Mentkevich G. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: Retrospective study of 45 cases. Am J Hematol 2003; 73: 225-229.
23. Lefrere F, Audat F, Hermine O, Cavazzana-Calvo M, Belanger C, Arnulf B et al. The timing of granulocytecolony-stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: A retrospective study of 65 cases. Transfusion 1999; 39: 561-564.
24. Castagnola E, Molinari AC, Fratino G, Viscoli C. Conditions associated with infections of indwelling central venous catheters in cancer patients: A summary. Br J Haematol 2003; 121: 233-239.
25. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: A meta-analysis of randomized controlled trials. Curr Med Res Opin 2007; 23: 2283-2295.